142 related articles for article (PubMed ID: 25109962)
1. The role of the bone morphogenetic proteins in leukaemic stem cell persistence.
Toofan P; Irvine D; Hopcroft L; Copland M; Wheadon H
Biochem Soc Trans; 2014 Aug; 42(4):809-15. PubMed ID: 25109962
[TBL] [Abstract][Full Text] [Related]
2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
3. Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis.
Toofan P; Wheadon H
Biochem Soc Trans; 2016 Oct; 44(5):1455-1463. PubMed ID: 27911727
[TBL] [Abstract][Full Text] [Related]
4. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
Lefort S; Maguer-Satta V
Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
[TBL] [Abstract][Full Text] [Related]
5. Targeting survival pathways in chronic myeloid leukaemia stem cells.
Sinclair A; Latif AL; Holyoake TL
Br J Pharmacol; 2013 Aug; 169(8):1693-707. PubMed ID: 23517124
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow niche crosses paths with BMPs: a road to protection and persistence in CML.
Busch C; Wheadon H
Biochem Soc Trans; 2019 Oct; 47(5):1307-1325. PubMed ID: 31551354
[TBL] [Abstract][Full Text] [Related]
7. Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
Grockowiak E; Laperrousaz B; Jeanpierre S; Voeltzel T; Guyot B; Gobert S; Nicolini FE; Maguer-Satta V
Blood; 2017 Dec; 130(26):2860-2871. PubMed ID: 29138221
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
Agarwal P; Isringhausen S; Li H; Paterson AJ; He J; Gomariz Á; Nagasawa T; Nombela-Arrieta C; Bhatia R
Cell Stem Cell; 2019 May; 24(5):769-784.e6. PubMed ID: 30905620
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
10. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
11. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.
Toofan P; Busch C; Morrison H; O'Brien S; Jørgensen H; Copland M; Wheadon H
Cell Death Dis; 2018 Sep; 9(9):927. PubMed ID: 30206237
[TBL] [Abstract][Full Text] [Related]
13. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
14. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
15. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
16. Stem Cell Guardians - Old and New Perspectives in LSC Biology.
Horne GA; Jackson L; Helgason V; Holyoake TL
Curr Drug Targets; 2017; 18(4):405-413. PubMed ID: 27411711
[TBL] [Abstract][Full Text] [Related]
17. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
18. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
19. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
20. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Cheloni G; Tanturli M; Tusa I; Ho DeSouza N; Shan Y; Gozzini A; Mazurier F; Rovida E; Li S; Dello Sbarba P
Blood; 2017 Aug; 130(5):655-665. PubMed ID: 28576876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
